EUVIMEDEUVIMED entdecken
Crossref

Single-nucleotide-resolution genomic maps of O6-methylguanine from the glioblastoma drug temozolomide

Kubitschek, Jasmina, Vakil Takhaveev, Cécile Mingard, Martha I Rochlitz, Patricia B. Reinert, Giulia Keller, Tom Kloter, Raúl Fernández Cereijo, Sabrina M. Huber, Maureen McKeague, Shana J. Sturla

Repository for Publications and Research Data (ETH Zurich) · 27.01.2025

DOI: 10.3929/ethz-b-000718164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Repository for Publications and Research Data (ETH Zurich), erschienen am 27.01.2025. Verfasst von Kubitschek und 11 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide kills cancer cells by forming O⁶-methylguanine (O⁶-MeG), which leads to cell cycle arrest and apoptosis. However, O⁶-MeG repair by O⁶-methylguanine-DNA methyltransferase (MGMT) contributes to drug resistance. Characterizing genomic profiles of O⁶-MeG could elucidate how O⁶-MeG accumulation is influenced by repair, but there are no methods to map genomic locations of O⁶-MeG. Here, we developed an immunoprecipitation- and polymerase-stalling-based method, termed O⁶-MeG-seq, to locate O⁶-MeG across the whole genome at single-nucleotide resolution. We analyzed O⁶-MeG formation and repair across sequence contexts and functional genomic regions in relation to MGMT expression in a glioblastoma-derived cell line. O⁶-MeG signatures were highly similar to mutational signatures from patients previously treated with temozolomide. Furthermore, MGMT did not preferentially repair O⁶-MeG with respect to sequence context, chromatin state or gene expression level, however, may protect oncogenes from mutations. Finally, we found an MGMT-independent strand bias in O⁶-MeG accumulation in highly expressed genes. These data provide high resolution insight on how O⁶-MeG formation and repair are impacted by genome structure and nucleotide sequence. Further, O⁶-MeG-seq is expected to enable future studies of DNA modification signatures as diagnostic markers for addressing drug resistance and preventing secondary cancers.

Schlagwörter

O6-methylguaninetemozolomideglioblastomaO6-methylguanine-DNA methyltransferasemutational signaturesdrug resistancestrand biaschromatin statesecondary cancer prevention

Zitieren

APA

Kubitschek, Jasmina, Takhaveev, V., Mingard, C., Rochlitz, M. I., Reinert, P. B., Keller, G., Kloter, T., Cereijo, R. F., Huber, S. M., McKeague, M., & Sturla, S. J. (2025). Single-nucleotide-resolution genomic maps of O6-methylguanine from the glioblastoma drug temozolomide. Repository for Publications and Research Data (ETH Zurich). https://doi.org/10.3929/ethz-b-000718164

Vancouver

Kubitschek, Jasmina, Takhaveev V, Mingard C, Rochlitz MI, Reinert PB, et al. Single-nucleotide-resolution genomic maps of O6-methylguanine from the glioblastoma drug temozolomide. Repository for Publications and Research Data (ETH Zurich). 2025. doi:10.3929/ethz-b-000718164

BibTeX
@article{Kubitschek2025,
  author = {Kubitschek and Jasmina and Takhaveev, Vakil and Mingard, Cécile and Rochlitz, Martha I and Reinert, Patricia B. and Keller, Giulia and Kloter, Tom and Cereijo, Raúl Fernández and Huber, Sabrina M. and McKeague, Maureen and Sturla, Shana J.},
  title = {Single-nucleotide-resolution genomic maps of O6-methylguanine from the glioblastoma drug temozolomide},
  journal = {Repository for Publications and Research Data (ETH Zurich)},
  year = {2025},
  doi = {10.3929/ethz-b-000718164}
}
Kostenlos starten →